STOCK TITAN
  1. Home
  2. News
  3. VDRM
  4. ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance

ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
ViaDerma Inc (VDRM), a specialty pharmaceutical company, has issued a statement confirming its continued operations amid concerns. The company acknowledged it has overdue annual and quarterly financial reports and is actively working to complete them. Management emphasized that the company is not defunct and continues to pursue its business objectives while exploring strategic options for future growth. The brief announcement appears aimed at addressing investor concerns about the company's operational status and regulatory compliance efforts.
ViaDerma Inc (VDRM), un'azienda farmaceutica specializzata, ha rilasciato una dichiarazione confermando la continuità delle sue attività nonostante alcune preoccupazioni. La società ha riconosciuto di avere rapporti finanziari annuali e trimestrali in ritardo e sta lavorando attivamente per completarli. La direzione ha sottolineato che l'azienda non è cessata e continua a perseguire i propri obiettivi commerciali, esplorando al contempo opzioni strategiche per la crescita futura. L'annuncio breve sembra volto a rassicurare gli investitori riguardo allo stato operativo della società e agli sforzi per la conformità normativa.
ViaDerma Inc (VDRM), una compañía farmacéutica especializada, ha emitido un comunicado confirmando la continuidad de sus operaciones en medio de ciertas preocupaciones. La empresa reconoció que tiene informes financieros anuales y trimestrales pendientes y está trabajando activamente para completarlos. La dirección enfatizó que la compañía no está inactiva y continúa persiguiendo sus objetivos comerciales mientras explora opciones estratégicas para el crecimiento futuro. El breve anuncio parece estar dirigido a tranquilizar a los inversores sobre el estado operativo de la empresa y sus esfuerzos de cumplimiento regulatorio.
전문 제약회사인 ViaDerma Inc(VDRM)는 우려 속에서도 계속 운영 중임을 확인하는 성명을 발표했습니다. 회사는 연간 및 분기 재무 보고서가 지연되고 있음을 인정하며 이를 완료하기 위해 적극적으로 노력하고 있습니다. 경영진은 회사가 폐업하지 않았으며 사업 목표를 계속 추구하는 한편 미래 성장을 위한 전략적 옵션도 모색 중임을 강조했습니다. 이 간단한 발표는 회사의 운영 상태와 규제 준수 노력에 대한 투자자들의 우려를 해소하기 위한 것으로 보입니다.
ViaDerma Inc (VDRM), une entreprise pharmaceutique spécialisée, a publié une déclaration confirmant la poursuite de ses activités malgré certaines inquiétudes. La société a reconnu avoir des rapports financiers annuels et trimestriels en retard et travaille activement à leur finalisation. La direction a souligné que l'entreprise n'est pas en cessation d'activité et continue de poursuivre ses objectifs commerciaux tout en explorant des options stratégiques pour sa croissance future. Cette brève annonce semble destinée à rassurer les investisseurs sur le statut opérationnel de l'entreprise et ses efforts de conformité réglementaire.
ViaDerma Inc (VDRM), ein spezialisiertes Pharmaunternehmen, hat eine Erklärung veröffentlicht, in der es die Fortführung seiner Geschäftstätigkeit trotz bestehender Bedenken bestätigt. Das Unternehmen räumte ein, dass Jahres- und Quartalsberichte überfällig sind und arbeitet aktiv an deren Fertigstellung. Das Management betonte, dass das Unternehmen nicht aufgelöst ist und weiterhin seine Geschäftsziele verfolgt, während es strategische Optionen für zukünftiges Wachstum prüft. Die kurze Mitteilung scheint darauf abzuzielen, Anleger über den operativen Status des Unternehmens und die Bemühungen um regulatorische Compliance zu beruhigen.
Positive
  • None.
Negative
  • Company has failed to file required annual and quarterly financial reports
  • Trading restricted to OTC Expert Market, indicating compliance issues
  • Lack of specific timeline for completing overdue financial reports

LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, today announced that it remains fully operational and is actively working to complete its overdue annual and quarterly financial reports.

The company is not defunct and continues to pursue its business objectives. ViaDerma is currently exploring all strategic options to move the company forward in the most effective manner possible.

About ViaDerma, Inc.
ViaDerma, Inc. (OTC Expert Market: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative transdermal drug delivery technology solutions to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, please visit: https://viaderma.com.

Any forecast of future performance is a "forward-looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

Contact information:
Investor Relations
Email: ir@viaderma.com
Phone: 310-734-6111


FAQ

Is ViaDerma (VDRM) still in business in 2025?

Yes, ViaDerma confirmed it remains fully operational and is not defunct, though it is working to complete overdue financial reports.

Why is VDRM stock trading on the OTC Expert Market?

VDRM trades on the OTC Expert Market likely due to compliance issues, including overdue annual and quarterly financial reports.

What financial reports are missing for ViaDerma (VDRM)?

The company has overdue annual and quarterly financial reports, though specific periods were not disclosed in the announcement.

What strategic options is ViaDerma (VDRM) exploring?

While the company stated it is exploring strategic options, no specific details were provided about the nature of these options.
Stock VDRM logo
Viaderma

OTC:VDRM

VDRM Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

VDRM Latest News

Jan 21, 2025
ViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and Progress Towards Product Registration in India
Dec 10, 2024
ViaDerma Announces Significant 2024 Achievements and International Expansion
Oct 3, 2024
ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow Growth
Sep 10, 2024
ViaDerma Completes First Shipment of 500,000 Units to Nigeria
Aug 13, 2024
ViaDerma Announces Shipment of 500,000 Units of its Flagship Product to Nigeria

VDRM Stock Data

20.97M
983.56M
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Marina del Rey

Related Articles

Continue reading with these related stories

View All Latest News